Nonadherence to Oral Antihyperglycemic Agents: Subsequent Hospitalization and Mortality among Patients with Type 2 Diabetes in Clinical Practice by Zhu, Vivienne J. et al.
Nonadherence to Oral Antihyperglycemic Agents: Subsequent Hospitalization  
and Mortality among Patients with Type 2 Diabetes in Clinical Practice 
Vivienne J. Zhu
a
, Wanzhu Tu
b
, Marc B. Rosenman
a,b
, J. Marc Overhage
c
 
aRegenstrief Institute, IN, USA bIndiana University School of Medicine, IN, USA,  
and cCerner Corporation, Malvern, PA, USA 
 
Abstract 
Using real-world clinical data from the Indiana Network for 
Patient Care, we analyzed the associations between non-
adherence to oral antihyperglycemic agents (OHA) and 
subsequent diabetes-related hospitalization and all-cause 
mortality for patients with type 2 diabetes.  OHA adherence 
was measured by the annual proportion of days covered 
(PDC) for 2008 and 2009.  Among 24,067 eligible patients, 
35,507 annual PDCs were formed.  Over 90% (n=21,798) of 
the patients had a PDC less than 80%.  In generalized linear 
mixed model analyses, OHA non-adherence is significantly 
associated with diabetes related hospitalizations (OR: 1.2; 
95% CI [1.1,1.3]; p<0.0001).  Older patients, white patients, 
or patients who had ischemic heart disease, stroke, or renal 
disease had higher odds of hospitalization.  Similarly, OHA 
non-adherence increased subsequent mortality (OR: 1.3; 95% 
CI [1.02, 1.61]; p<0.0001).  Patient age, male gender, income 
and presence of ischemic heart diseases, stroke, and renal 
disease were also significantly associated with subsequent all-
cause death. 
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Background 
Type 2 diabetes is a major public health crisis in this country.  
Over 29 million adults in the United States currently have 
diabetes mellitus, and the incidence is increasing at nearly 
epidemic rates [1]. This will have a significant public health 
impact because diabetes is a major cause of morbidity and 
mortality.  In addition, healthcare costs are 11% higher for 
patients with poorly controlled diabetes compared to those 
with good glycemic control [2]. 
Clearly, pharmacotherapy for glycemic control is essential to 
achieving the goal of long-term metabolic control and 
reducing the risk of cardiovascular disease (CVD) events, the 
primary cause of hospitalization and mortality among these 
patients. However, increasing evidence suggests that patients 
with diabetes often have poor adherence to prescribed 
medication therapies.  A systematic review of medication 
adherence in diabetes showed low adherence rates, ranging 
between 36-87% across numerous studies [3].  These 
observations have been replicated in several studies, and 
adherence among patients with diabetes is disappointingly 
low, dropping most dramatically after the first six months of 
therapy [4,5]. 
Improving medication adherence is viewed as a high priority 
for health care reform.  The Centers for Medicare and 
Medicaid Service (CMS) has encouraged adherence to oral 
diabetes medications via quality and efficiency measures in 
health and drug plan performance rating [6].  However, 
improving medication adherence is a multifactorial challenge. 
Health information technology (HIT) and health information 
exchange (HIE) are playing an increasing role in generating, 
measuring, and transferring important medication adherence 
data between hospitals, pharmacies, providers, and patients. 
Recently, the electronic medical record system (EMR) 
meaningful use criteria and the Accountable Care 
Organization (ACO) have encouraged electronic prescribing, 
medication reconciliation, patients’ accessibility to their own 
medical information, and care coordination [7,8], all of which 
support improving medication adherence and ultimately 
improving patient health outcomes through HIT and HIE.  
Although the effects of medication adherence on patient 
hospitalization and mortality, as well as the significant 
potential of HIT and HIE for improving medication 
adherence, have been increasingly recognized, few 
population-based studies have been conducted using real-
world data.   The association between medication non-
adherence and mortality has been chiefly demonstrated in 
clinical trials.  In this study, we aimed to assess adherence to 
OHA for patients with type 2 diabetes and to analyze the 
association between OHA non-adherence and hospitalization 
and mortality, using real-world clinical data from an 
operational HIE. 
Methods 
Data sources and settings 
This retrospective study was designed to analyze the 
association between nonadherence to oral antihyerglycemic 
agents (OHA) and health outcomes in the subsequent year for 
patients with type 2 diabetes. We used medication dispensing 
data from 2008 to 2009 and clinical data (hospitalization and 
death) from 2009 to 2010 from the Indiana Network for 
Patient Care (INPC).  The INPC is an operational, regional, 
health information exchange that included over 100 hospitals, 
physician practices, payers, pharmacies, laboratories, and 
independent radiology centers.  This system delivers medical 
record information from hospitals, laboratories, imaging 
centers, pharmacies and physician offices [9]. In particular the 
INPC included pharmacy claims data from the largest public 
and private payers as well as medication history data from 
pharmacy benefit managers obtained via the Surescripts 
network [10].  For this study, the patient medication history, 
diabetes related hospitalizations, and death (all causes)  
information were extracted from the INPC and were linked 
through a robust linkage algorithm.  We additionally 
estimated patient income through median household income 
by zip code obtained from the U.S. Census Bureau website 
(2000 data is the most recently information available).  This 
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study was approved by the Institutional Review Board of 
Indiana University and the INPC Management Committee. 
Eligibility criteria 
Eligible subjects were age 18 years or older in 2008, and had a 
diagnosis of type 2 diabetes using the International 
Classification of Disease, Ninth Revision, Clinical 
Modification (ICD-9_CM) of 250.x0 and 250.x2.  They had at 
least one pharmacy claim for an OHA: Biguanides, 
Sulfonylurea (SU), Thiazolidinedione (TZD), other OHAs 
(Meglitinides and α- glucosidase), or OHA combination. 
Patient OHA dispensing information was extracted by the 
National Drug Codes (NDC) with drug names matched to 
OHA medications identified by the First DataBank Standard 
Therapeutic Code system (STC:71, excluding injectable: 
0177, A771, A716), from 2008 to 2009.  Patients who used 
insulin were excluded. This sample reflects patients who had a 
drug benefit.  Also, since all included subjects had in fact 
filled a prescription, it suggests that they used that benefit.  
Therefore, it is likely that the data collected accurately reflects 
the pattern of medication dispensing events.  
Measurements 
The independent variable is the annual OHA medication 
adherence for 2008 and 2009, which was measured using a 
standard approach: the proportion of days covered (PDC).  
The PDC is an accepted standard measurement for evaluating 
medication adherence using retrospective data.  It is defined as 
the total number of medication-covered days divided by the 
number of days in a certain time period.   In this study, the 
annual PDC is calculated as the proportion of days which had 
at least one OHA available during a 365-day period. 
Medication history data, including refill date, days of supply, 
dosage, and frequency, are used to calculate PDC [11].  For 
patients who took multiple OHAs, we calculated the 
combined PDC.  Non-adherence was defined as a PDC less 
than 80%, a conventional cut- off point to define poor 
adherence for chronic conditions [12]. 
The dependent variables were diabetes hospitalization and all-
cause death for 2009 and 2010 
(2010 is the most recent year for which death certificate data 
are available in the INPC).  For each patient, we identify 
whether a diabetes-related hospitalization occurred in 2009 or 
2010 according to the primary diagnosis for inpatient 
admissions in the INPC.  Patients who had at least one 
recorded hospitalization related to diabetes type 2 (ICD-9: 
250.*2), cardiovascular disease (ICD-9:410.*. 411.*, 412.*, 
414.*), stroke (ICD-9:433.*1, 434.*), or renal disease (ICD- 
9:585.*) during a study year were considered to have a DM2 
related hospitalization. Similarly, the patient’s vital status also 
was identified from the INPC which was previously integrated 
from the Social Security Administration. 
In order to control possible confounders that may influence 
patient hospitalization and mortality, we examined age, 
gender, race, income, number of concurrent OHAs (single, 
multiple), and baseline co-morbidities (hypertension, ischemic 
heart diseases, stroke, and renal disease) as covariates. 
Statistical analyses 
Patient OHA adherence was assessed.  Descriptive statistics of 
patient demographic and clinical characteristics, 
hospitalizations, and mortality were reported for both the 
adherent and non-adherent groups. Continuous variables were 
compared using t-tests, and categorical variables were 
compared using χ2 tests.  Generalized linear mixed models 
(GLMMIX) were performed to evaluate the association 
between hospitalization or mortality and OHA adherence of 
the previous year in the INPC DM2 population. Random 
subject effects were used in these models to accommodate the 
potential association among observations contributed by the 
same study subjects. Adjusted odds ratios (OR) were used to 
quantify the associations.  All analyzes were implemented 
using SAS 9.1 (SAS Institute, Cary, North Carolina).  Two-
sided p-values less than 0.05 were considered significant. 
Results 
A total of 24,067 eligible patients with DM2 were identified 
for this study from 2008 to 2010, and 35,069 annual PDC 
were formed.  Across the study period, 21,798 (90.6%) of the 
patients had a mean annual PDC of less than 80%.  A total of 
4,235 (17.9%) patients had at least one DM2 related 
hospitalization, and 319 (1.3%) patients died by 2010.  Patient 
characteristics by adherence are outlined in Table 1.  Non-
adherent patients were relatively younger (60 vs 67), more 
were female (52% vs. 49%), fewer were white (81% vs 87%), 
and they had relatively lower income ($45,447 vs $46,872).   
Around 70% of patients had hypertension in both groups.  The 
rates of hypertension and ischemic heart disease  was slightly 
lower in the non-adherent group, but no significant difference 
was found for stroke and renal disease between the two 
groups. 
Table 1– Patient characteristics 
 Adherent 
(N=2,269) 
Nonadherent 
(N=21,798)
 N (%) N (%)
Age at study entry† 67.0 (12.1) 60.4 (15.1) 
Female gender 1,114 (49.1) 11,369 (52.2) 
Race   
Asian 7 (0.3) 52 (0.2) 
African-American 289 (12.7) 3,869 (18.1) 
Hispanic 4 (0.2) 158 (0.7) 
White 1,969 (86.8) 17,628 (80.9) 
Multiple OHA agents 683 (30.1) 6,771 (31.1) 
Hospitalization  377 (16.6) 3,945 (18.1) 
Death 25 (1.1) 294 (1.3) 
Comorbidity   
Hypertension 1,665 (73.4) 15,163 (69.6) 
Ischemic heart disease 570 (25.1) 4,893 (22.5) 
Stroke 54 (2.4) 536 (2.5) 
Renal disease 192 (8.5) 1,669 (7.7) 
Median income ($) † 46,872 (9,303) 45,447 (12,654) 
† mean (SD)   
Table 2– Association between adherence,  
hospitalization, and death 
 Hospitalization Death 
Odds Ratio (95%CI) Odds Ratio (95%CI)
Non-adherence 1.21 (1.12, 1.31) 1.28 (1.02, 1.61)
Age (10 yr incments) 1.06 (1.02, 1.20) 1.85 (1.10, 1.91
Female gender 1.14 (1.08, 1.31) 0.80 (0.65, 0.95)
Race (ref=’White)   
Asian 0.19 (0.06, 0.60) 1.10 (0.16, 8.85)†
African-American 0.79 (0.73, 086) 0.75 (0.59, 0.96)
Hispanic 0.47 (0.29, 0.74) 0.71 (0.17, 2.90)†
Comorbidity   
Hypertension 1.01 (0.94, 1.07)† 0.65 (0.54, 0.79)
Ischemic heart disease 1.82 (1.70, 1.95) 1.24 (1.02, 1.52)
Stroke 1.56 (1.42, 1.71) 2.09 (1.68, 2.89)
Renal disease 1.42 (1.23, 1.64) 2.06 (1.49, 2.89)
Multiple OHAs 0.89 (0.82, 0.92) 0.96 (0.79, 1.15)†
Income ($10,000) 0.99 (0.92, 1.06)† 0.87 (0.82, 0.94)
† p-value >0.05     
Compared with adherent patients, patients who did not adhere 
to OHA had significantly higher hospital admission rates 
(18.1% vs. 16.6%) and higher  
V.J. Zhu et al. / Nonadherence to Oral Antihyperglycemic Agents 61
mortality (1.35% vs. 1.1%).  Table 2 summarizes the results of 
the GLIMMIX model that analyzed associations between 
OHA adherence, patient factors and subsequent DM2 related 
hospitalizations and mortality. After adjusting for patient 
baseline characteristics, OHA non-adherence is significantly 
associated with hospitalizations (OR: 1.2; 95% CI [1.1, 1.3]; 
p<0.0001). Older patients, whites, or patients who had 
ischemic heart disease, stroke, or renal disease had greater 
odds of hospitalization. Similarly, OHA non-adherence 
increased subsequent death due to any cause (OR: 1.3; 95% 
CI [1.0, 1.6]; p<0.0001).   Patient age, male gender, and 
presence of a co-morbid condition (including ischemic heart 
diseases, stroke, or renal disease) were also significantly 
associated with subsequent death. Hypertension had no effect 
on hospitalization (p=0.84) but was associated with lower risk 
of death (OR; 0.5; 95% CI [0.54, 0.79]; p<0.001). Multiple 
OHA use decreased risk of hospitalizations, but had no 
significant association with death.   Patient income had no 
association with hospitalization, but it was inversely 
associated with all-cause death. 
Discussion 
This large, population-based, observational study documented 
a high prevalence (90%) of non-adherence to OHA in clinical 
practice.  In the multivariable GLIMMIX analyses, after fully 
adjusting for baseline patient demographic and clinical 
characteristics, non-adherent patients had a 1.2 fold higher 
risk for hospitalization with diabetes, cardiovascular diseases, 
or renal disease in the subsequent year.  In addition, we 
observed significantly increased rates of all-cause mortality 
(OR: 1.3) among patients who did not adhere to OHA. These 
findings are consistent with previous population-based 
studies.  Joe Hong, et al., reported that non-adherence to OHA 
in the first two years increased the risk of hospitalization (OR: 
1.26) and death (OR: 1.4) in the third year among patients in a 
national insurance program [13]; Lau and Nau found a 2.5 
times higher risk for diabetes and cardiovascular disease 
hospitalization among non-adherent patients within one year 
using a registry [14]; Ho, et al., showed medication non-
adherence was significantly associated with all-cause 
hospitalization (OR: 1.6) and all cause-mortality (OR: 1.8) in 
12 months of follow up of an randomized clinical trial [15]; 
Glycemic control is the primary goal for diabetes 
management.  Oral antihyperglycemic therapies are effective 
methods to control glycemic levels among patients with type 2 
diabetes, thus lowering their risks of developing 
microvascular and macrovascular complications [16]; 
Previous studies have shown that OHA adherence was 
independently associated with HbA1c control: HbA1c 
decreases 0.10% to 0.16% for each 10% increment in OHA 
adherence [17]; As a result, improving OHA adherence may 
lead to better patient health outcomes through better glycemic 
control.  Our study confirmed the importance of OHA 
adherence in clinical practice.  Patients who did not adhere to 
their OHA medication (PDC less than 80%) were at higher 
risk of both hospitalization and mortality within one year. 
In addition to the therapeutic effectiveness of OHA adherence, 
good adherence could also be a surrogate for other factors that 
reflect a high quality of care, healthy behavior, or more 
effective treatment. Patients who adhere to OHA may be more 
compliant with other medications, such as HMG-CoA 
reductase inhibitors and beta-blockers, to better control 
complications. They may also more actively implement self-
management, including monitoring blood glucose levels, 
following a diet, engaging in regular exercise, caring for their 
feet, and interacting with providers, which all lead to 
improved clinical outcomes in diabetes.  In contrast, non-
adherence may be associated with depression, cognitive 
impairment, or missed appointments, which may be linked to 
less than desirable health outcomes. 
This study also found that older patients and those with 
ischemic heart diseases, stroke, and/or renal diseases had 
higher risks of both hospitalization and death.  Interventions 
for improving medication adherence or other intensive care 
should target these subgroups so that patients can achieve the 
full benefits of anti-hyperglycemic therapies. Interestingly, 
hypertension was not significantly associated with 
hospitalization and decreased risk of death, which is 
inconsistent with the notion that hypertension accelerates the 
progression of both micro- and macro-vascular complications 
in diabetes.   A possible explanation could be that aggressive 
antihypertensive treatments, including a range of 
antihypertensive drugs and lifestyle therapies, might be 
applied to diabetic hypertensive patients to reduce the risk of 
micro-vascular and macro-vascular disease [18].   
Studies about socioeconomic status and patient health 
outcomes have shown mixed results. Our study found no 
association between income and hospitalization, while 
patients with lower income had higher risk of all-cause death.  
The study subjects are mainly resident in the central Indiana 
region and have insurance coverage (including Medicaid), 
with which they might have been provided equal access to the 
healthcare system.  However, low income may directly 
influence mortality by other context, such as health behaviors, 
stress, suicide, and homicide, as well as environmental factors 
[19]. 
The main findings from this study add evidence to the 
growing need to establish interventions in medication 
adherence in order to improve health outcomes for patients 
with type 2 diabetes.  Barriers to medication adherence in 
diabetes exist at the patient, medication, and provider levels, 
and a multi-dimensional approach is required to establish 
efficient interventions.  Health HIT and HIE offer the 
potential to establish such a system.  First, objective and data-
driven approaches can be programmatically established 
through an HIE. Second, computerized alerts and reminders 
can notify pharmacists or prescribers when their patients miss 
an opportunity to fill a medication in routine clinical practice.  
Third, predictive modeling may identify patients who are at 
higher risk of medication non-adherence and may help 
evaluate specific barriers for these patients.  Fourth, widely 
used Internet and mobile health technologies may empower 
patients to manage their medications.  In addition, a well-
established HIE/HIT could support patient-centric and team-
based care that better engages patients, providers, and health 
care systems for improving medication adherence. 
Several limitations should be noted.  First, the OHA 
dispensing information was extracted from the Surescript in 
the INPC covered geographic area; findings may not apply to 
other population.  Second, dispensing claims might not reflect 
patient medication-taking behavior if patients did not actually 
use these medications.  Nevertheless, filling a prescription is 
usually consistent with taking the medication. Third, findings 
from this observational study demonstrated associations (not 
causations) between OHA non-adherence and hospitalization, 
as well as associations (not causations) between OHA non-
adherence and mortality.  Fourth, some patients with type 2 
diabetes may use insulin to control their glycemic levels; 
however, we lack information regarding insulin use for this 
population.  In addition, we were not able to identify the 
specific cause of death using existing data; therefore, the 
association between OHA adherence and mortality might be 
overestimated. 
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Conclusions  
This study found that 90% of patients with type 2 diabetes did 
not adhere to oral antihyperglycemic agents in clinical 
practice.  Nonadherence was significantly associated with 
increased risks of hospitalization and death in the following 
year.  The study findings emphasize the importance of 
improving medication adherence in diabetes management.  
Developing HIT and HIE strategies should be highly 
encouraged to effectively intervene with patients and 
providers regarding medication adherence. 
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